Analytical Validation of Blood and Tissue Biomarkers: Biospecimen Requirements
Trans-Hit Biomarkers, whose mission is to accelerate the development and validation of new biomarkers, has an objective to raise the awareness of the scientific community, both academia and industry, of the care they should take when using human specimens for discovering, developing and validating new biomarkers.
Following on from a well-received initial webinar, Trans-Hit Biomarkers now wants to provide participants with a better understanding of the studies required to achieve an appropriate analytical validation of blood biomarkers (immunoassays, blood-based genomic assays) and tissues biomarkers (immunohistochemistry). After hearing to three experts in biomarkers assays development, participants should be able to better understand the biospecimen needs and requirements for these studies.
Who Should Attend:
• Biomarker Scientists from academia or industry
• Biobanks: Pathologists, Clinical chemists, Managers
• Biospecimen Procurement department from Industry
Dr. W. Jeffrey Allard, Ph.D. - Chief Executive Officer - Lakeside Life Science– USA
Dr. Mark Kockx, MD, Ph.D., Pathologist - Chief Executive Officer - HistoGenex, Belgium
Dr. Steve Kleiboeker, Ph.D. - Vice President - Research & Development - Viracor Eurofins Clinical Diagnostics - USA